{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:13:29Z","timestamp":1786997609724,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.transproceed.2021.07.043","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T23:58:27Z","timestamp":1629244707000},"page":"2261-2266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Predictors of Transplant-Associated Thrombotic Microangiopathy in Patients With Overlap or Chronic Graft-vs-Host-Disease"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-8208","authenticated-orcid":false,"given":"Eleni","family":"Gavriilaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Sakellari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Chatzikonstantinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoi","family":"Bousiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Mallouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Masmanidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eudoxia-Evaggelia","family":"Koravou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foteini","family":"Kika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasoula","family":"Touloumenidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolia","family":"Papalexandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Yannaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Batsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achilles","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2021.07.043_bib0001","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/bmt.2017.39","article-title":"Transplant-associated thrombotic microangiopathy: opening Pandora's box","volume":"52","author":"Gavriilaki","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0002","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fimmu.2019.00337","article-title":"Complement in thrombotic microangiopathies: unraveling Ariadne's thread into the labyrinth of complement therapeutics","volume":"10","author":"Gavriilaki","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0003","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1055\/s-0039-1692721","article-title":"Linking complement activation, coagulation, and neutrophils in transplant-associated thrombotic microangiopathy","volume":"119","author":"Gavriilaki","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0004","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1055\/s-0040-1702225","article-title":"Pretransplant genetic susceptibility: clinical relevance in transplant-associated thrombotic microangiopathy","volume":"120","author":"Gavriilaki","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0005","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0006","first-page":"1049","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0007","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy","volume":"127","author":"Jodele","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0008","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/bmt.2016.87","article-title":"Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy","volume":"51","author":"Vasu","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0009","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC","volume":"99","author":"de Fontbrune","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0010","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.bbmt.2017.08.019","article-title":"Thrombotic microangiopathy after allogeneic stem cell transplantation: a comparison of eculizumab therapy and conventional therapy","volume":"23","author":"Bohl","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0011","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1172\/JCI136094","article-title":"Complementopathies and precision medicine","volume":"130","author":"Gavriilaki","year":"2020","journal-title":"J Clin Investig"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0012","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/bloodadvances.2020001515","article-title":"Interferon-complement loop in transplant-associated thrombotic microangiopathy","volume":"4","author":"Jodele","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0013","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.bbmt.2008.05.022","article-title":"low body mass index is an independent risk factor for transplant-associated microangiopathy following total-body irradiation-based conditioning regimens","volume":"14","author":"Kaloyannidis","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0014","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1440-1827.2011.02704.x","article-title":"Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"61","author":"Mii","year":"2011","journal-title":"Pathol Int"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0015","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/01.tp.0000230373.82376.46","article-title":"Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Uderzo","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0016","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ajh.20648","article-title":"Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation","volume":"81","author":"Nakamae","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0017","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bbmt.2005.04.007","article-title":"Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Cutler","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0018","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bbmt.2012.10.006","article-title":"Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus\/sirolimus-based graft-versus-host disease prophylaxis","volume":"19","author":"Shayani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0019","doi-asserted-by":"crossref","first-page":"e13371","DOI":"10.1111\/ctr.13371","article-title":"Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation","author":"Gavriilaki","year":"2018","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0020","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hon.2346","article-title":"Transplant-associated thrombotic microangiopathy: an unresolved complication of unrelated allogeneic transplant for hematologic diseases","volume":"35","author":"Sakellari","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0021","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1002\/acn3.50909","article-title":"Neurologic complications after allogeneic transplantation: a meta-analysis","volume":"6","author":"Gavriilaki","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0022","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fmed.2020.00212","article-title":"An update in drug-induced thrombotic microangiopathy","volume":"7","author":"Chatzikonstantinou","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0023","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0024","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbmt.2016.11.023","article-title":"Survival advantage and comparable toxicity in reduced-toxicity treosulfan-based versus reduced-intensity busulfan-based conditioning regimen in myelodysplastic syndrome and acute myeloid leukemia patients after allogeneic hematopoietic cell transplantation","volume":"23","author":"Sakellari","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0025","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/jca.21660","article-title":"Favorable impact of extracorporeal photopheresis in acute and chronic graft versus host disease: prospective single-center study","volume":"33","author":"Sakellari","year":"2018","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0026","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00277-018-3383-9","article-title":"Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study","volume":"97","author":"Sakellari","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0027","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcv.2018.02.012","article-title":"Donor EBV at the time of hematopoietic cell transplantation: is it time to adopt molecular assays?","volume":"102","author":"Sakellari","year":"2018","journal-title":"J Clin Virol"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0028","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0029","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0030","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.clml.2017.06.008","article-title":"The role of low-dose anti-thymocyte globulin as standard prophylaxis in mismatched and matched unrelated hematopoietic peripheral stem cell transplantation for hematologic malignancies","volume":"17","author":"Sakellari","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 1","key":"10.1016\/j.transproceed.2021.07.043_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jdv.12311","article-title":"Guidelines on the use of extracorporeal photopheresis","volume":"28","author":"Knobler","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0032","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0033","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S2352-3026(17)30108-4","article-title":"EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis","volume":"4","author":"Luft","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0034","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/bloodadvances.2018013060","article-title":"How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD","volume":"2","author":"Jaglowski","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0035","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0036","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jaci.2016.11.022","article-title":"Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation","volume":"139","author":"Weinacht","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0037","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109799","article-title":"Pharmacologic blockade of JAK1\/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect","volume":"9","author":"Choi","year":"2014","journal-title":"PLOS One"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0039","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/bloodadvances.2019032268","article-title":"External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation","volume":"3","author":"Shouval","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0040","first-page":"1049","article-title":"Complement blockade for TA-TMA: lessons learned from large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0041","article-title":"Improved survival following OMS721 treatment of hematopoieic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA)","author":"Rambaldi","year":"2018","journal-title":"EHA"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0042","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0043","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.10699","article-title":"Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an international working group","volume":"92","author":"Ruutu","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.transproceed.2021.07.043_bib0044","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134521005248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134521005248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:37:43Z","timestamp":1758577063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134521005248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0041134521005248"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2021.07.043","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of Transplant-Associated Thrombotic Microangiopathy in Patients With Overlap or Chronic Graft-vs-Host-Disease","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2021.07.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}